Evicenter
P&T meetings

Molgramostim Inhalation Solution

Autoimmune pulmonary alveolar proteinosis

Manufacturer
Savara
Regulatory submission
BLA resubmitted December 2025
Launch
Not announced
Last updated
89 sources

Executive summary

Burden of Autoimmune pulmonary alveolar proteinosis

1 evidence topic · 3 sources

Summary

A Japanese registry reported a minimum incidence of 0.49 per million and prevalence of 6.2 per million for autoimmune pulmonary alveolar proteinosis. Reported symptoms include shortness of breath, cough, fatigue, and reduced exercise capacity. In a retrospective cohort of 104 participants with autoimmune pulmonary alveolar proteinosis, 35 (34%) were hospitalized because of infection.